NASDAQ:LJPC - La Jolla Pharmaceutical Stock Price, Forecast & News

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

La Jolla Pharmaceutical (NASDAQ:LJPC) released its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.05) by $0.03. The biopharmaceutical company had revenue of $5.71 million for the quarter, compared to analysts' expectations of $6.96 million. La Jolla Pharmaceutical had a negative net margin of 683.88% and a negative return on equity of 715.11%. View La Jolla Pharmaceutical's Earnings History.

La Jolla Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for La Jolla Pharmaceutical.

4 analysts have issued 1-year price objectives for La Jolla Pharmaceutical's shares. Their forecasts range from $19.00 to $20.00. On average, they anticipate La Jolla Pharmaceutical's share price to reach $19.50 in the next twelve months. This suggests a possible upside of 181.4% from the stock's current price. View Analyst Price Targets for La Jolla Pharmaceutical.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for La Jolla Pharmaceutical.

News headlines about LJPC stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. La Jolla Pharmaceutical earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for La Jolla Pharmaceutical.

La Jolla Pharmaceutical saw a decrease in short interest in the month of February. As of February 14th, there was short interest totalling 3,220,000 shares, a decrease of 11.5% from the January 30th total of 3,640,000 shares. Based on an average daily trading volume, of 1,340,000 shares, the short-interest ratio is presently 2.4 days. Approximately 12.5% of the shares of the company are sold short. View La Jolla Pharmaceutical's Current Options Chain.

Some companies that are related to La Jolla Pharmaceutical include Avrobio (AVRO), Cellectis (CLLS), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Rubius Therapeutics (RUBY), Proteon Therapeutics (PRTO), MeiraGTx (MGTX), Aptose Biosciences (APTO), Replimune Group (REPL), Atara Biotherapeutics (ATRA), GENFIT S A/ADR (GNFT), Prevail Therapeutics (PRVL), Nantkwest (NK), Compugen (CGEN) and Scholar Rock (SRRK).

Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), Intercept Pharmaceuticals (ICPT), El Pollo LoCo (LOCO), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sarepta Therapeutics (SRPT), XOMA (XOMA), Juno Therapeutics (JUNO), Inovio Pharmaceuticals (INO) and Advanced Micro Devices (AMD).

La Jolla Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional investors include Broadfin Capital LLC (9.90%), FMR LLC (4.62%), Alyeska Investment Group L.P. (2.37%), State Street Corp (1.58%), Geode Capital Management LLC (1.29%) and Assenagon Asset Management S.A. (1.05%). Company insiders that own La Jolla Pharmaceutical stock include Darryl Wellinghoff, George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for La Jolla Pharmaceutical.

LJPC stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, SG Americas Securities LLC, Spark Investment Management LLC, Oxford Asset Management LLP, New York State Common Retirement Fund, Charles Schwab Investment Management Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for La Jolla Pharmaceutical.

LJPC stock was purchased by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Alyeska Investment Group L.P., Assenagon Asset Management S.A., Goldman Sachs Group Inc., Jacobs Levy Equity Management Inc., Acadian Asset Management LLC, Grimes & Company Inc. and UBS Group AG. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include Darryl Wellinghoff, George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla and Perceptive Advisors Llc. View Insider Buying and Selling for La Jolla Pharmaceutical.

Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LJPC stock can currently be purchased for approximately $6.93.

La Jolla Pharmaceutical has a market capitalization of $188.20 million and generates $10.06 million in revenue each year. The biopharmaceutical company earns $-199,470,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. La Jolla Pharmaceutical employs 169 workers across the globe.View Additional Information About La Jolla Pharmaceutical.

The official website for La Jolla Pharmaceutical is http://www.lajollapharmaceutical.com/.

La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]